This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of the Safety and Effectiveness of the DuraHeart™ LVAS

This study has been terminated.
(Insufficient enrollment)
Information provided by (Responsible Party):
Terumo Heart Inc. Identifier:
First received: July 2, 2008
Last updated: October 20, 2016
Last verified: October 2016

Specific Aims The aims of this trial are to evaluate the safety and effectiveness of the DuraHeart™ LVAS in patients with advanced heart failure who require LVAS support as a bridge to cardiac transplantation.

Study Population The patient population for this trial consists of patients with end stage heart failure awaiting cardiac transplantation. Patients must be listed for transplant with UNOS with status 1A or 1B. All patients who meet the eligibility criteria may be included in the study regardless of gender, race or ethnicity.

Study Design This is a multi-center, prospective, single arm study in which the lower one-sided confidence interval exceeds the performance goal. Enrollment is expected to occur within an 18-month time period at up to 40 centers. All patients will be followed for all endpoints for 6 months while on DuraHeart™ LVAS support, or until cardiac transplantation or death, whichever occurs first. For those patients who remain on support after 180 days, survival and device reliability data will continue to be collected on a regular basis. If patients are transplanted, survival at day 30 post cardiac transplantation will also be assessed.

Condition Intervention
Heart Failure Device: DuraHeart Left Ventricular Assist System (LVAS)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Safety and Effectiveness of the DuraHeart™ Left Ventricular Assist System in Patients Awaiting Transplantation

Resource links provided by NLM:

Further study details as provided by Terumo Heart Inc.:

Primary Outcome Measures:
  • Survival to cardiac transplantation or to 180 days post implantation and listed for cardiac transplantation in categories UNOS 1A or 1B. [ Time Frame: 180 days ]

Secondary Outcome Measures:
  • Survival to 180 days or Transplanted [ Time Frame: 180 days ]
  • Incidence of adverse events [ Time Frame: 180 days ]
  • Quality of life [ Time Frame: Baseline, 1 month, 6 months, and annually ]
  • Functional status [ Time Frame: Baseline, 1 month, 3 months, 6 months, and annually ]

Enrollment: 66
Study Start Date: July 2008
Estimated Study Completion Date: January 2018
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Historical Data
DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a "bridge to transplant" until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients
Device: DuraHeart Left Ventricular Assist System (LVAS)
The DuraHeart LVAS is implanated in using open heart surgery
Other Name: LVAD


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The following are general criteria; more specific conditions are included in the study protocol:

  1. Approved for cardiac transplantation
  2. Listed with UNOS on the Status 1 list
  3. Patient for whom LVAS implantation is planned as a clinically indicated bridge to cardiac transplantation

Exclusion Criteria:

The following are general criteria; more specific conditions are included in the study protocol:

  1. Contraindication to the administration of warfarin or anti-platelet agents
  2. Primary coagulopathy or platelet disorder
  3. Acute myocardial infarction within 48 hours prior to enrollment
  4. Anticipated need for RVAD support or ECMO at the time of LVAS implantation
  5. Prior cardiac transplantation, left ventricular reduction surgery, cardiomyoplasty, passive restraint device (i.e., CorCapTM Cardiac Support Device) or surgically implanted left ventricular assist device
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00710567

  Show 26 Study Locations
Sponsors and Collaborators
Terumo Heart Inc.
Principal Investigator: Francis D. Pagani, M.D., Ph.D. University of Michigan
Principal Investigator: Yoshifumi Naka, M.D., Ph.D. Columbia University
Principal Investigator: David S Feldman, MD Minneapolis Heart Institute
  More Information

Responsible Party: Terumo Heart Inc. Identifier: NCT00710567     History of Changes
Other Study ID Numbers: DH003
Study First Received: July 2, 2008
Last Updated: October 20, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Terumo Heart Inc.:
Heart Failure
Rotary Pump

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases processed this record on August 18, 2017